Dexamethasone or Prednisone: Which One Should Be the Corticosteroid of Choice in Patients With Pemphigus Vulgaris?

Dexamethasone or Prednisone: Which One Should Be the Corticosteroid of Choice in Patients With Pemphigus Vulgaris? Publisher Pubmed

Hatami P¹ ; Balighi K^{1, 2} ; Mohandesi NA³ ; Nicknam Asl H⁴ ; Aryanian Z^{1, 5}

Show Affiliations

1. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
3. Department of Dermatology, Mayo Clinic, Rochester, MN, United States
4. Department of Dentistry, Rafsanjan University of Medical Sciences (RUMS), Rafsanjan, Iran
5. Department of Dermatology, Babol University of Medical Sciences, Babol, Iran

Source: Dermatologic Therapy Published:2022

Abstract

[No abstract available]

Related Docs

View other Related Docs

1. Kaposi's Sarcoma in a Patient With Pemphigus Vulgaris Mimicking Exacerbation of Pemphigus, Cancer Reports (2023)

2. Sars-Cov-2 Vaccination and Practical Points in Psoriasis Patients: A Narrative Review, Dermatologic Therapy (2022)

3. Covid Outcome in Pemphigus: Does Rituximab Make Pemphigus Patients Susceptible to More Severe Covid-19?, Journal of Cosmetic Dermatology (2023)

4. Epidemiology, Clinical Presentation, and Management of Pemphigoid Nodularis: An Update From Iran, Dermatologic Therapy (2022)

5. A 10-Year Survey on Lichen Planus Pemphigoides in Iran: A Therapeutic Conundrum, Dermatologic Therapy (2022)

6. Covid-19 Vaccination in Children As a Global Dilemma Through an Ethical Lens: A Retrospective Review, Health Science Reports (2023)

7. Prevalence and Management of Chronic Hepatitis B in Pemphigus and Pemphigoid Patients: New Evidence for the Safety of Rituximab, Dermatologic Therapy (2022)

8. Serious Health Threat of Mucormycosis During the Ongoing Covid-19 Pandemic: What Dermatologists Need to Know in This Regard, International Journal of Dermatology (2022)

Experts (# of related papers)

View all Related Experts

Zeinab Aryanian (13)

Kamran Balighi (12)

Style	Citing Format
MLA	Hatami P, et al.. "Dexamethasone or Prednisone: Which One Should Be the Corticosteroid of Choice in Patients With Pemphigus Vulgaris?." Dermatologic Therapy, vol. 35, no. 7, 2022, pp. -.
APA	Hatami P, Balighi K, Mohandesi NA, Nicknam Asl H, Aryanian Z (2022). Dexamethasone or Prednisone: Which One Should Be the Corticosteroid of Choice in Patients With Pemphigus Vulgaris?. Dermatologic Therapy, 35(7), -.
Chicago	Hatami P, Balighi K, Mohandesi NA, Nicknam Asl H, Aryanian Z. "Dexamethasone or Prednisone: Which One Should Be the Corticosteroid of Choice in Patients With Pemphigus Vulgaris?." Dermatologic Therapy 35, no. 7 (2022): -.
Harvard	Hatami P et al. (2022) 'Dexamethasone or Prednisone: Which One Should Be the Corticosteroid of Choice in Patients With Pemphigus Vulgaris?', Dermatologic Therapy, 35(7), pp. -.
Vancouver	Hatami P, Balighi K, Mohandesi NA, Nicknam Asl H, Aryanian Z. Dexamethasone or Prednisone: Which One Should Be the Corticosteroid of Choice in Patients With Pemphigus Vulgaris?. Dermatologic Therapy. 2022;35(7):-.
BibTex	@article{ author = {Hatami P and Balighi K and Mohandesi NA and Nicknam Asl H and Aryanian Z}, title = {Dexamethasone or Prednisone: Which One Should Be the Corticosteroid of Choice in Patients With Pemphigus Vulgaris?}, journal = {Dermatologic Therapy}, volume = {35}, number = {7}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Hatami P AU - Balighi K AU - Mohandesi NA AU - Nicknam Asl H AU - Aryanian Z TI - Dexamethasone or Prednisone: Which One Should Be the Corticosteroid of Choice in Patients With Pemphigus Vulgaris? JO - Dermatologic Therapy VL - 35 IS - 7 SP - EP - PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract